EUVIMEDEUVIMED entdecken
Crossref

PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay

J. Tate Thigpen

Clinical Ovarian Cancer · 2011

DOI: 10.1016/j.cloc.2012.02.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von J. Tate Thigpen. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Thigpen, J. T. (2011). PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2012.02.002

Vancouver

Thigpen JT. PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2012.02.002

BibTeX
@article{Thigpen2011,
  author = {Thigpen, J. Tate},
  title = {PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay},
  journal = {Clinical Ovarian Cancer},
  year = {2011},
  doi = {10.1016/j.cloc.2012.02.002}
}
Kostenlos starten →